| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/01/1999 | WO1999015525A1 Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them |
| 04/01/1999 | WO1999015524A1 Thiazole derivatives |
| 04/01/1999 | WO1999015523A1 Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors |
| 04/01/1999 | WO1999015522A1 Tetrahydrofuran phosphate- and hydroxy esters, as prodrugs for the corresponding antifungal agent |
| 04/01/1999 | WO1999015521A1 Benzothiophenes |
| 04/01/1999 | WO1999015508A1 Vitronectin receptor antagonists |
| 04/01/1999 | WO1999015507A1 Hydrazono-benzazulene derivatives, pharmaceutical compositions and intermediates |
| 04/01/1999 | WO1999015506A1 Tricyclic compounds, preparation method and said method intermediates, application as medicines and pharmaceutical compositions containing same |
| 04/01/1999 | WO1999015505A1 1,5-diphenylpyrazole derivatives |
| 04/01/1999 | WO1999015504A1 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein |
| 04/01/1999 | WO1999015503A2 Process for making diaryl pyridines useful as cox-2 inhibitors |
| 04/01/1999 | WO1999015501A1 Specific immunophilin ligands useful as anti-asthmatic, anti-allergic, anti-rheumatic, immunosuppressive, antipsoriatic and neuroprotective agents |
| 04/01/1999 | WO1999015500A1 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 04/01/1999 | WO1999015498A1 New npy antagonists |
| 04/01/1999 | WO1999015494A1 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 04/01/1999 | WO1999015493A1 9,10-dihydro-9,10-ethanoanthracene derivatives as phospholipase inhibitors |
| 04/01/1999 | WO1999015490A1 C3a receptor ligands |
| 04/01/1999 | WO1999015487A1 Benzyl-biphenyls and analogous compounds and the application thereof in order to treat arteriosclerosis and dyslipidaemia |
| 04/01/1999 | WO1999015203A1 Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms |
| 04/01/1999 | WO1999015202A1 Remedies for dysuria resulting from prostatic hypertrophy |
| 04/01/1999 | WO1999015194A1 Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
| 04/01/1999 | WO1999015187A1 Antiviral polymers comprising acid functional and hydrophobic groups |
| 04/01/1999 | WO1999015186A1 Cationic polymers as toxin-binding agents |
| 04/01/1999 | WO1999015185A1 Agent for modifying the proliferation, functional activity and death of natural and tumoral cells |
| 04/01/1999 | WO1999015183A1 PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES |
| 04/01/1999 | WO1999015182A1 New use for budesonide and formoterol |
| 04/01/1999 | WO1999015181A1 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) and its use as medicament for treating excess of glucocorticoids |
| 04/01/1999 | WO1999015180A1 Coated dosage units |
| 04/01/1999 | WO1999015179A1 Methods of limiting apoptosis of cells |
| 04/01/1999 | WO1999015178A1 Vitronectin receptor antagonist |
| 04/01/1999 | WO1999015177A1 Treatment of attention-deficit/hyperactivity disorder |
| 04/01/1999 | WO1999015176A1 Treatment of oppositional defiant disorder |
| 04/01/1999 | WO1999015175A1 Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection |
| 04/01/1999 | WO1999015174A1 Reverse prenyl compounds as immunosuppressants |
| 04/01/1999 | WO1999015173A1 Compositions and methods for treating respiratory disorders |
| 04/01/1999 | WO1999015172A1 Medicament formulation with a controlled release of an active agent |
| 04/01/1999 | WO1999015171A1 Nicotine compositions and methods of formulation thereof |
| 04/01/1999 | WO1999015170A1 Vitronectin receptor antagonist |
| 04/01/1999 | WO1999015169A1 Thrombin inhibitors |
| 04/01/1999 | WO1999015168A1 Method for reducing radiation toxicity |
| 04/01/1999 | WO1999015167A2 Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer |
| 04/01/1999 | WO1999015166A1 Parasiticidal formulations |
| 04/01/1999 | WO1999015165A1 Topical non-steroidal anti-inflammatory drug composition |
| 04/01/1999 | WO1999015164A1 Amide derivatives for the treatment of diseases mediated by cytokines |
| 04/01/1999 | WO1999015163A1 Treatment of conduct disorder |
| 04/01/1999 | WO1999015161A2 Inhibition of psychostimulant-induced and nicotine-induced craving |
| 04/01/1999 | WO1999015160A2 Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 04/01/1999 | WO1999015159A2 Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| 04/01/1999 | WO1999015157A2 G2 checkpoint inhibitors and assay |
| 04/01/1999 | WO1999015156A1 Inhibition of crystallization in transdermal devices |
| 04/01/1999 | WO1999015155A1 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient |
| 04/01/1999 | WO1999015153A1 Small particle liposome aerosols for delivery of anti-cancer drugs |
| 04/01/1999 | WO1999015150A1 Inorganic-polymer complexes for the controlled release of compounds including medicinals |
| 04/01/1999 | WO1999015149A1 Method and composition for causing skin lightening |
| 04/01/1999 | WO1999015148A1 Resorcinol derivatives |
| 04/01/1999 | WO1999015147A2 Use of alkylmonoglucosides as molecular vectors |
| 04/01/1999 | WO1999015035A1 Smoking products containing antioxidants |
| 04/01/1999 | WO1999015016A1 Methods for regulating trka expression |
| 04/01/1999 | WO1999015013A2 Use of quaternary carboxylic acid alkanolamine ester salts as microbicidal agents |
| 04/01/1999 | WO1999014998A2 Method for preventing and treating hearing loss using sensorineurotrophic compounds |
| 04/01/1999 | WO1999003878A3 Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis |
| 04/01/1999 | WO1999003826A3 Metalloproteinase inhibitors |
| 04/01/1999 | WO1999002673A3 Antisense oligonucleotide sequences as inhibitors of microorganisms |
| 04/01/1999 | WO1999002545A3 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 04/01/1999 | WO1999002541A3 Erythromycin a oxime solvates |
| 04/01/1999 | WO1999002497A3 Pyridine derivatives |
| 04/01/1999 | WO1999002133A3 Topical application of a combination of benzoyl peroxide and a second active ingredient |
| 04/01/1999 | WO1999001117A3 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins |
| 04/01/1999 | WO1999000117A3 Neuroprotective methods and reagents |
| 04/01/1999 | WO1998057614A3 Physiological combination of active substances to enhance the skin's defenses against noxious agents |
| 04/01/1999 | WO1998056812A3 Estrogen receptor crystals and ligands |
| 04/01/1999 | WO1998056370A3 Therapeutic nanospheres |
| 04/01/1999 | WO1998054313A3 Dna methyltransferase genomic sequences and antisense oligonucleotides |
| 04/01/1999 | WO1998052898A9 Pharmaceutical agents for the treatment of cerebral amyloidosis |
| 04/01/1999 | WO1998052573A9 Triterpene saponin analogs having adjuvant and immunostimulatory activity |
| 04/01/1999 | WO1998051787A3 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety |
| 04/01/1999 | WO1998051321A9 Tissue factor for influencing blood vessel formation |
| 04/01/1999 | WO1998051294A3 Method and composition for treating cancers |
| 04/01/1999 | WO1998048785A3 Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| 04/01/1999 | WO1998032429A3 P2 receptor agonists, antagonists and modulators of endogenous atp release for the treatment of skin conditions and the improvement of wound healing |
| 04/01/1999 | WO1998030900A8 Screening method for compounds active in treating myopia and hypermetropia |
| 04/01/1999 | WO1998014592A3 Telomerase reverse transcriptase |
| 04/01/1999 | DE19743323A1 Solid selegiline dosage form |
| 04/01/1999 | DE19743143A1 Pharmazeutische Kombinationspräparate Pharmaceutical combination preparations |
| 04/01/1999 | DE19742717A1 Synergistic combination of endothelin antagonist and renin-angiotensin system inhibitor |
| 04/01/1999 | DE19742612A1 Budesonid zur Behandlung von cholestatischen Lebererkrankungen Budesonide for the treatment of cholestatic liver diseases |
| 04/01/1999 | DE19742263A1 Neue spezifische Immunophilin-Liganden als Antiasthmatika, Antiallergika, Antirheumatika, Immunsuppressiva, Antipsoriatika, Neuroprotektiva New specific immunophilin ligands as anti-asthmatics, anti-allergic, anti-inflammatory drugs, immunosuppressants, anti-psoriasis, neuroprotective agents |
| 04/01/1999 | DE19742222A1 Verwendung von quaternären Carbonsäurealkanolaminestersalzen als mikrobizide Wirkstoffe Use of quaternary Carbonsäurealkanolaminestersalzen as microbicidal agents |
| 04/01/1999 | DE19740879A1 Use of flavone derivatives for controlling bacteria |
| 04/01/1999 | CA2309357A1 Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection |
| 04/01/1999 | CA2304961A1 Methods and compositions for binding hematopoietic stem cells |
| 04/01/1999 | CA2304879A1 New tetracycles, process for their production and pharmaceutical preparations containing these compounds |
| 04/01/1999 | CA2304849A1 Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors |
| 04/01/1999 | CA2304783A1 Method of identification of leads or active compounds |
| 04/01/1999 | CA2304647A1 Method for preventing and treating hearing loss using sensorineurotophic compounds |
| 04/01/1999 | CA2304638A1 G2 checkpoint inhibitors and assay |
| 04/01/1999 | CA2304622A1 Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-?b via the ubiquitin proteasome pathway to treat inflammatory and autoimmunediseases |
| 04/01/1999 | CA2304592A1 Inhibition of psychostimulant-induced and nicotine-induced craving |
| 04/01/1999 | CA2304505A1 Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| 04/01/1999 | CA2304452A1 Method and composition for causing skin lightening |